

Online Resource 3


Manuscript: Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once Daily Efavirenz 400 mg and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Journal: Clinical Pharmacokinetics

Authors: Laura Dickinson, Janaki Amin, Laura Else, Marta Boffito, Deirdre Egan, Andrew Owen, Saye Khoo, David Back, Catherine Orrell, Amanda Clarke, Marcelo Losso, Praphan Phanuphak, Dianne Carey, David A Cooper, Sean Emery, Rebekah Puls, on behalf of the ENCORE1 study group

Corresponding Author Details: Laura Dickinson, Department of Molecular & Clinical Pharmacology, University of Liverpool. laurad@liv.ac.uk

Online Resource 3 Mean individual predicted efavirenz concentrations at 12 hours post-dose (C_{12}) on a log scale stratified for metaboliser status (extensive, intermediate, slow) and dose (400 mg and 600 mg once daily; $n=310$ and $n=295$, respectively). The black dashed line illustrates the recommended minimum effective concentration for efavirenz (MEC) of 1.0 mg/L. Each point represents an individual patient and the solid black line the median concentrations. Numbers of patients with C_{12} below the MEC or with detectable or missing viral load at 96 weeks are shown ($n=1$ patient excluded; receiving 800 mg efavirenz during pharmacokinetic sampling).



	400 mg efavirenz				600 mg efavirenz			
	Extensive	Intermediate	Slow	Missing	Extensive	Intermediate	Slow	Missing
Number of patients (<i>n</i>)	119	128	48	15	107	127	39	22
$C_{12}<1.0$ mg/L (<i>n</i>)	10	2	2	0	3	1	2	0
$VL\geq 200$ copies/mL (<i>n</i>)	3	5	2	0	1	2	0	0
Missing VL (<i>n</i>)	3	6	4	1	4	4	6	3
$C_{12}<1.0$ mg/L								
&	1	0	0	0	0	1	0	0
$VL\geq 200$ copies/mL (<i>n</i>)								